HERTFORDSHIRE, England and
PITTSBURGH, Dec. 4, 2015 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced the pricing of a private
placement of $1 billion aggregate principal amount of senior
notes, comprised of $500 million
aggregate principal amount of 3.000% senior notes due 2018 at an
issue price of 99.874% and $500
million aggregate principal amount of 3.750% senior notes
due 2020 at an issue price of 99.968%. Mylan intends to use the net
proceeds from the offering to repay the amounts outstanding under
its revolving credit facility and its accounts receivable
securitization facility and to finance a portion of the repurchase
of its ordinary shares pursuant to its previously announced share
repurchase program. Subject to customary closing conditions, the
sale of the notes is expected to close on or about December 9, 2015.
The notes will be sold only to qualified institutional buyers in
the United States in reliance on
Rule 144A under the Securities Act of 1933, and outside
the United States to non-U.S.
persons in reliance on Regulation S under the Securities Act. The
proposed issuance of the notes will not be registered under the
Securities Act, and may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, any securities, nor shall there be
any sale of securities mentioned in this press release in any state
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state.
This press release contains forward-looking statements
relating to the consummation of the offering described above and
the anticipated use of proceeds therefrom. Consummation of the
offering is subject to a number of conditions, some of which are
beyond Mylan's control. Therefore, no assurance can be given that
the offering will be consummated on the terms described or at all,
or that the proceeds will be able to be deployed as
indicated.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,400 generic and branded pharmaceuticals,
including antiretroviral therapies on which nearly 50% of people
being treated for HIV/AIDS in the developing world depend. We
market our products in approximately 165 countries and territories.
Our global R&D and manufacturing platform includes more than 50
facilities, and we are one of the world's largest producers of
active pharmaceutical ingredients. Every member of our more than
30,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-announces-pricing-of-senior-notes-300188405.html
SOURCE Mylan N.V.